Breaking News, Collaborations & Alliances

Selexis, Pieris Pharma Enter Cell Line Pact

Focus of deal is on Pieris’ immuno-oncology bispecific drug candidate

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Selexis SA, a provider of mammalian (suspension-adapted CHO-K1) cell line generation, has signed a license agreement that provides Pieris Pharmaceuticals with access to Selexis SUREtechnology Platform and SURE CHO-M Cell Line to advance the development of PRS-343, Pieris’ lead bispecific immuno-oncology drug candidate. PRS-343 is a CD137/HER2 bispecific that is designed to promote CD137 clustering by bridging CD137-positive T cells with HER2-positive tumor cells, thereby providing a potent costi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters